Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens

Journal of Urology

Volumn 163, Issue 4, 2000, Pages 1155-1160

  Stamey, Thomas A ^a   Yemoto, Cheryl M ^a   McNeal, John E ^a   Sigal, Bronislava M ^a   Johnstone, Iain M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neoplasm staging; Prostate; Prostate specific antigen; Prostatectomy; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE; TREATMENT FAILURE;

EID: 0034023763     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67713-0     Document Type: Article

References (30)

1. Schmid, H.-P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71: 2031, 1993
2. Whittemore, A. S., Lele, C., Friedman, G. D. et al: Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst, 87: 354, 1995
3. Stamey, T. A., McNeal, J. E., Yemoto, C. M. et al: Biological determinants of cancer progression in men with prostate cancer. JAMA, 281: 1395, 1999
4. Cox, D. R. and Oakes, D.: Analysis of Survival Data. New York: Chapman and Hall, 1984
5. Stamey, T. A., Dietrick, D. D. and Issa, M. M.: Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J Urol, 149: 510, 1993
6. Erbersdobler, A., Hammerer, P., Huland, H. et al: Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol, 158: 1594, 1997
7. McNeal, J. E., Villers, A. A., Redwine, E. A. et al: Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol, 14: 240, 1990
8. McNeal, J. E., Villers, A. A., Redwine, E. A. et al: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990
9. McNeal, J. E. and Yemoto, C. E.: Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol, 20: 802, 1996
10. McNeal, J. E. and Yemoto, C. E.: Significance of demonstrable vascular space invasion for the progression of prostatic adenocarcinoma. Am J Surg Pathol, 20: 1351, 1996
11. Prestigiacomo, A. F. and Stamey, T. A.: A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol, 152: 1515, 1994
12. Stamey, T. A.: Lower limits of detection, biological detection limits, functional sensitivity or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin Chem, 42: 849, 1996
13. Venables, W. N. and Ripley, B. D.: Modern Applied Statistics S-PLUS, 2nd ed. New York: Springer-Verlag, p. 357, 1997
14. Cox, D. R. and Snell, E. J.: Analysis of Binary Data, 2nd ed. New York: Chapman and Hall, appendix 2, 1989
15. Mosteller, F. and Tukey, J. W.: Data Analysis and Regression New York: Addison-Wesley, 1977
16. Copas, J. B.: Regression, prediction and shrinkage. J R Stat Soc, series B, 45: 311, 1983
17. Ripley, B. D.: Pattern recognition and neural networks. Cambridge: Cambridge University Press, 1996
18. Stamey, T. A., Sözen, T. S., Yemoto, C. M. et al: Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol, 159: 2009, 1998
19. Partin, A. W., Yoo, J., Carter, H. B. et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol, 150: 110, 1993
20. Partin, A. W., Kattan, M. W., Subong, E. N. P. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA, 277: 1445, 1997
21. Cohen, P., Peehl, D. M., Graves, H. C. et al: Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol, 142: 407, 1994
22. Peehl, D. M.: Prostate specific antigen role and function. Cancer, suppl., 75: 2021, 1995
23. 125I prostate implant followed by external-beam radiation. Cancer J Sci Am, 4: 359, 1998
24. Epstein, J. I., Carmichael, M., Partin, A. W. et al: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol, 149: 1478, 1993
25. Epstein, J. I., Partin, A. W., Sauvageot, J. et al: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol, 20: 286, 1996
26. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol, 152: 1837, 1994
27. Pruthi, R. S., Johnstone, I., Tu, I. P. et al: Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology, 49: 737, 1997
28. Stamey, T. A.: Making the most out of six systematic sextant biopsies. Urology, 45: 2, 1995
29. Bauer, J. J., Connelly, R. R., Seterhenn, I. A. et al: Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol, 159: 929, 1998
30. Kattan, M. W., Eastham, J. A., Stapleton, A. M. et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998